Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.10EUR
11:35am EDT
Change (% chg)

€-0.09 (-0.85%)
Prev Close
€11.19
Open
€11.20
Day's High
€11.27
Day's Low
€11.10
Volume
25,393
Avg. Vol
146,596
52-wk High
€14.69
52-wk Low
€8.21

Latest Key Developments (Source: Significant Developments)

Ablynx to receive 15 million euros milestone payment
Monday, 22 May 2017 01:00am EDT 

May 22 (Reuters) - ABLYNX NV ::NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT.ABLYNX ANNOUNCED THAT IT HAS COMPLETED PREPARATION OF A PRE-CLINICAL PACKAGE FOR A NOVEL NANOBODY® (ALX-1141) IN OSTEOARTHRITIS.AS PART OF ONGOING COLLABORATION BETWEEN ABLYNX AND MERCK KGAA <<>>, MERCK HAS ACCEPTED PRE-CLINICAL PACKAGE AND THIS HAS TRIGGERED A EUR 15 MILLION MILESTONE PAYMENT TO ABLYNX.MERCK IS NOW RESPONSIBLE FOR FURTHER CLINICAL DEVELOPMENT OF MOLECULE.  Full Article

Ablynx Q1 revenues eur 9.1 million (2016 eur 27.4 million)
Thursday, 11 May 2017 01:03am EDT 

May 11 (Reuters) - ABLYNX NV ::Q1 REVENUES EUR 9.1 MILLION (2016: EUR 27.4 MILLION).Q1 OPERATING LOSS OF EUR 20.2 MILLION (2016: LOSS EUR 0.7 MILLION).COMPANY REITERATES ITS NET CASH BURN GUIDANCE FOR FULL-YEAR 2017 TO BE IN RANGE OF EUR 75-85 MILLION..FINANCIAL GUIDANCE AND 2017 OUTLOOK CONFIRMED.Q1 NET CASH OUTFLOW OF EUR 26.2 MILLION (2016: EUR 2.5 MILLION).EXPECTS TO COMMUNICATE TOPLINE RESULTS FROM PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ATTP IN SECOND HALF OF 2017.Q1 EUR 209.2 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND SHORT-TERM INVESTMENTS (2016: EUR 233.7 MILLION).DATA ARE EXPECTED TO BE USED TO SUPPORT RECENTLY SUBMITTED MAA IN EUROPE AND PLANNED BIOLOGICS LICENSE APPLICATION FILING IN USA IN 2018.  Full Article

Ablynx announces warrant exercise
Friday, 21 Apr 2017 01:02am EDT 

April 21 (Reuters) - Ablynx NV ::Announces warrant exercise.An additional 57,125 common shares have been issued by company in exchange for EUR 398,801.77 ($427,395.86) as result of exercise of warrants.As a result of this transaction, co now has 61,133,199 shares outstanding.  Full Article

Ablynx FY revenue rises 10 pct
Thursday, 23 Feb 2017 01:00am EST 

Ablynx Nv : FY total revenues of EUR 85.2 million (+10%) . FY cash position of EUR 235.4 million . FY net cash burn of EUR 72.2 million, in line with previously guided range of EUR 65-75 million . FY net loss EUR 1.1 million versus loss of EUR 54.5 million year ago .FY operating loss EUR 28.6 million versus loss of EUR 17.6 million year ago.  Full Article

Ablynx submits marketing authorisation for caplacizumab
Monday, 6 Feb 2017 01:00am EST 

Ablynx NV : Ablynx submits a marketing authorisation application to the European medicines agency for caplacizumab, its anti-vwf nanobody, for the treatment of aTTP . Ablynx is on track to report results of the confirmatory phase III HERCULES study in the second half of 2017 . In phase II TITAN study, treatment with caplacizumab significantly reduced time to platelet count normalisation and number of recurrences of aTTP while on drug treatment . Intends to lead the commercialisation of caplacizumab in Europe and North America .Post-Hoc analysis of the TITAN study demonstrated that caplacizumab dramatically reduced the number of patients experiencing major thromboembolic events while on drug treatment.  Full Article

Van Herk Investments announces 10.07 pct shareholding in Ablynx
Tuesday, 24 Jan 2017 01:00am EST 

Ablynx Nv :Van Herk Investments B.V. announces 10.07 pct shareholding in Ablynx, an increase from a former position of 5.40 pct (August 2016).  Full Article

Ablynx achieves first milestone in collaboration with Novo Nordisk
Wednesday, 30 Nov 2016 01:00am EST 

Ablynx NV : Ablynx achieves first milestone as part of collaboration with Novo Nordisk . Ablynx to receive 1 million euro ($1.06 million) success fee . Ablynx received an upfront license fee of 5 million euros and will receive up to 4 million euros in research funding during the initial three year research term of the collaboration .Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to 182 million euros plus tiered royalties on the annual net sales.  Full Article

FMR LLC announces 9.10 pct shareholding in Ablynx
Friday, 18 Nov 2016 01:00am EST 

Ablynx NV :FMR LLC announces 9.10 pct shareholding in Ablynx.  Full Article

Ablynx H1 net income turns to profit of 22.8 million euros
Thursday, 25 Aug 2016 01:00am EDT 

Ablynx NV : H1 total revenues were 53.5 million euros ($60.3 million), a 39 pct increase compared with 2015 . H1 operating loss reduced to 2.0 million euros, compared with 7.4 million euros in 2015 . H1 net profit of 22.8 million euros versus loss of 15.2 million euros year ago .Outlook for remainder of year confirmed.  Full Article

Bank of America Corporation announce 5.24 pct shareholding in Ablynx
Thursday, 4 Aug 2016 01:00am EDT 

Ablynx NV :Bank of America Corporation announce 5.24 pct shareholding in Ablynx.  Full Article

More From Around the Web

BRIEF-Ablynx to receive 15 million euros milestone payment

* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT